StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) bonds

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)

Close on Nov 18, 2026Market cap $10.06MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$32.78M
$11.71M due within a year
Net debt
-$67.38M
After $100.16M of cash
Implied interest rate
8.57%
FY2025 interest ÷ average debt
Interest coverage
-49.0×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in TScan Therapeutics's 10-Q for the period ended Jun 30, 2026

TScan Therapeutics's filings do not break debt down by note

The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawnExpires
Silicon Valley Bank$52.50M$32.50MSep 1, 2028
Tranche One–$32.50M–

See a number that looks wrong?